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Accumulated knowledge in the molecular processes of tumour development combined with the availability of genetically
modiﬁed viruses resemble the basis for new promising cancer therapeutics. The main advantages of employing replication-
competent viruses are achievement of tumour selective killing and ampliﬁcation of their oncolytic potential within the tumour
mass. In this review, we describe the development of ONYX-015, one of the ﬁrst and most advanced replication-competent
viruses for cancer therapy. We discuss the molecular biology of this therapeutic approach and the interesting results obtained
with this virus in clinical trials.
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Research on DNA-viruses helped to elucidate basic cellular func-
tions such as DNA replication and gene transcription. These
efforts also demonstrated the oncogenic potential of some viruses
and led to a detailed understanding of the molecular tools viruses
use to achieve their biologic goals. Most fascinatingly, it is evident
that many viruses exploit for their replication the same pathways
that are altered in cancer cells. Frank McCormick and his group
at Onyx Pharmaceuticals were the ﬁrst to propose taking advantage
of this similarity in creating a virus that would selectively replicate
in and destroy tumour cells carrying mutations of the p53 tumour
suppressor gene (Bischoff et al, 1996). This review summarizes the
molecular biologic rationale for the adenovirus mutant dl1520
(now designated ONYX-015 or CI-1042), which has been used to
test the possibility of tumour-selective virus replication and it
summarizes the ongoing debate over the basic mechanisms
involved in replication of ONYX-015. We will provide an up-date
on the clinical development of this virus and outline a perspective
for its future development.
Cell cycle control in cancer cells
Tumorigenesis is a multistep process in which mutations in genes
involved in cell cycle control and apoptosis accumulate over time
(Christofori and Hanahan, 1994; Vogelstein and Kinzler, 1993).
Inactivation of tumour suppressors and activation of proto-onco-
genes leads to uncontrolled growth and cell division, hallmarks
of tumour development. It is now well established that there are
common targets of mutation events in cancer development. For
example, many tumours have defects in a pathway controlling cell
cycle progression that includes cyclin D1, cdk4, p16INK4a, and the
retinoblastoma protein (Rb; Figure 1; Sherr, 1996). Alterations of
this pathway lead to activation of the transcription factor E2F,
which promotes cell cycle progression from G1 to S phase. Like-
wise, most, if not all tumours characterized to date, have defects
in the p53 tumour suppressor pathway. Mutations involve either
p53 itself or proteins that control its activity or stability such as
p14ARF and Mdm2 (Lane, 1999; Levine et al, 1991; Steele et al,
1998). A variety of therapeutic approaches have been proposed that
target these anomalies frequent in cancer and differentiate malig-
nant cells unambiguously from normal cells. The agent discussed
here was one of the ﬁrst to directly target cells bearing mutations
in the p53 pathway.
p53 is a transcription factor that can block cell cycle
progression and induce apoptosis in response to cellular stress
or DNA damaging signals (Giaccia and Kastan, 1998; Levine,
1997). After DNA damage, the p53 protein becomes phosphory-
lated, is stabilized, and accumulates in the nucleus of the cells
(Caspari, 2000; Ljungman, 2000). Phosphorylation leads to confor-
mational changes that protect p53 from degradation via the
Mdm2-ubiquitin pathway (Momand et al, 1992; Haupt et al,
1997). In its role as a transcription factor, p53 binds to the promo-
ters of genes involved in cell cycle arrest and apoptosis, such as
p21
WAF1 and Bax, respectively (el-Deiry et al, 1993; Miyashita
and Reed, 1995).
The function of p53 is closely linked to the cellular machinery
promoting cell cycle progression. This became very clear when a
new tumour suppressor protein was identiﬁed, p14ARF, which is
induced by activation of E2F and acts as an upstream activator
of p53 (Bates et al, 1998; Palmero et al, 1998). p14ARF can bind
to Mdm2 and sequester it in the nucleolus of the cell keeping it
physically away from p53 thereby preventing p53’s degradation
(Sherr and Weber, 2000). The result of Mdm2 neutralization by
p14ARF is that p53 protein levels will rise and subsequently cause
cell cycle arrest and apoptosis. p14ARF also inhibits Mdm2’s
ubiquitin ligase activity through direct physical interaction (Honda
and Yasuda, 1999). Furthermore, recent studies have demonstrated
additional mechanisms for p14ARF’s function in controlling p53
activity independent of its ability to sequester Mdm2 in the nucleo-
lus (Weber et al, 1999). As the cellular p53 protein level rises, p53
binds to the promoter of the Mdm2 gene, stimulating its transcrip- Received 24 September 2001; accepted 5 October 2001
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p14ARF is encoded by the INK4a gene locus, which also contains
the gene for the cyclin dependent kinase inhibitor p16Ink4a
(Serrano, 1997). p16Ink4a is a component of the Rb pathway
and negatively regulates the activity of the cyclinD/cdk4 complexes
(Serrano, 1997). Importantly, the INK4a gene locus is frequently
targeted by mutations in a variety of human cancers, making it
the second most altered gene locus in tumours (Orlow et al,
1999; Thompson et al, 2001). Ampliﬁcations of the Mdm2 onco-
gene and loss of p14ARF have been reported as an alternative
mechanism of inactivating p53-dependent checkpoint control
(Cordon-Cardo et al, 1994). Defects in both pathways (Rb pathway
and p53 pathway) then allow tumour cells to escape protective
responses triggered by p53, such as growth arrest and apoptosis,
following activation of E2F by oncogenes or DNA-damage.
Cell cycle control by DNA-viruses
It has been known for many years that a variety of viruses are
capable of altering the cell cycle. Viruses have evolved to utilize
molecular factors in the infected cell in a way that allows maximiz-
ing their replication and production. In this respect, viruses and
cancer cells share a common goal: to replicate their DNA freely
and efﬁciently. Not surprisingly, viruses interfere with the same
signal transduction pathways that are altered in cancer, promoting
G1 to S-phase transition of the cell cycle. In particular, p53 and Rb
dependent cell cycle checkpoints are bypassed through virus
induced mechanisms.
Viruses have evolved gene products that either interact physi-
cally with cell cycle regulatory proteins or activate their
transcription, thereby mimicking cell cycle activation in quiescent
cells. One major function of the early adenoviral gene products,
such as E1A and E1B, is to push the infected cell into the S phase
of the cell cycle (Flint and Shenk, 1997), since it is necessary for the
virus in order to use the cellular DNA replication machinery to
replicate its own genome efﬁciently. The E1A proteins have been
shown to induce quiescent cells to enter S phase by binding to
Rb and thereby releasing free E2F (Flint and Shenk, 1997). On
the other hand, E1A also induces the expression of p14ARF and
subsequent accumulation of active p53 in the nucleus of the cell
(de Stanchina et al, 1998). This would lead to growth arrest of
the infected cell induced via a p21WAF1 triggered mechanism
(el-Deiry et al, 1993). p53 may also induce Bax, leading to cell
apoptosis before the viral life cycle has been completed (Miyashita
and Reed, 1995). In both cases viral yields would be signiﬁcantly
reduced. To circumvent this problem, adenoviruses encode another
set of early genes, the E1B genes (E1B55K and E1B19K); that
protect the infected cell from effects triggered by E1A-induced
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Figure 1 The interaction of adenovirus proteins with the Rb and p53 tumour suppressor pathways. Activating (?) and inactivating effects are indicated
( ) as well as protein phosphorylation events ( P).
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Figure 2 Abdominal CT-scans from a patient with liver metastases from colorectal cancer who received infusions of ONYX-015 into the hepatic artery in
combination with 5-FU and Leucovorin (i.v. bolus injection) as part of a phase-II clinical study (Table 1). Before enrollment into this study, the patient had
experienced disease progression despite treatment with different chemotherapeutic regimens 5-FU/Leucovorin and CPT-11 (Images courtesy of Dr T Reid
and Dr D Sze, Stanford University, Palo Alto, CA, USA).
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E1B19K protein is a functional homologue of the proto-oncogene
Bcl-2 and prevents apoptosis (Rao et al, 1992; Debbas and White,
1993). The E1B55K gene product is capable of binding p53 and
inactivating it (Kao et al, 1990). Together with another early viral
protein, the E4orf6 protein, E1B55K exports p53 to the cytoplasm
and targets it for degradation (Moore et al, 1996; Querido et al,
1997). Furthermore, at later times in infection, both proteins act
in concert to facilitate the transport of viral late mRNAs while
inhibiting the transport of most cellular mRNAs (Babiss et al,
1985; Halbert et al, 1985). It is noteworthy that other DNA viruses,
such as SV40 or HPV-16, also make efforts to eliminate p53. (Lane
and Crawford, 1979; Linzer and Levine, 1979; zur Hausen, 1991).
IN VITRO AND PRECLINICAL STUDIES
ONYX-015: selective replication in tumour cells with
altered p53 pathway
The striking similarities of tumour cells and adenovirus infected
cells gave rise to the concept of using a mutant adenovirus to
selectively eliminate tumour cells, which is based on the observa-
tion that in both, tumour cells and adenovirus infected cells,
p53 – in its role as ‘guardian of the genome’ – is a major
target for inactivation. ONYX-015 contains a 827 bp deletion
in the E1B region of the viral genome and a point mutation that
generates a premature stop codon preventing expression of a
truncated form of the E1B55K protein (Barker and Berk,
1987). Theses mutations render ONYX-015 incapable of blocking
p53’s function. Indeed, dl1520 is incapable of degrading p53, which
therefore accumulates in the nucleoplasm after infection of normal
(p53
+) cells. Infection of normal cells with ONYX-015 should
evoke a p53 response: either growth arrest or apoptosis, resulting
in aberrant viral replication. In contrast, tumour cells that do
not possess a functional p53 gene (p53
7 cells) should support
replication of ONYX-015. Replication of ONYX-015 should there-
fore be restricted to p53 deﬁcient cells resulting in selective
destruction of cancer cells.
Effects of ONYX-015 on tumour cells in vitro
In the ﬁrst experiments to test this hypothesis, ONYX-015’s ability
to grow was tested in tumour cell lines of known p53 status
(Bischoff et al, 1996). These experiments suggested a correlation
between p53 status of the tumour cell lines and susceptibility to
ONYX-015. Genetic experiments in tumour cell lines provided
further evidence for ONYX-015’s p53 selectivity. Functionally
p53-deﬁcient cell lines were derived from tumour cell lines with
wild-type p53 protein (RKO and A2780) by expression of a domi-
nant negative p53 allele. While ONYX-015 replication is not
supported in the parental cell lines, the p53 defective derivative
was killed at very low multiplicities of infection (MOI; Bischoff
et al, 1996; Rogulski et al, 2000b; Ganly et al, 2001). These experi-
ments provide genetic evidence for an important role of p53 in
response to virus infection and underscore the necessity for adeno-
virus to eliminate p53’s function in order to replicate efﬁciently.
In agreement with the initial hypothesis, investigations in
normal cells demonstrated that ONYX-015 does not replicate in
normal human mammary epithelial cells and microvascular
endothelial cells, while wild-type adenovirus is not restricted in
its replication in these cells under identical conditions (Heise et
al, 1997).
Subsequent work by several laboratories, however, found that a
variety of tumour cell lines with wild-type p53 allow efﬁcient repli-
cation of ONYX-015 (Goodrum and Ornelles, 1998; Rothmann et
al, 1998; Turnell et al, 1999). In a recent study, we were able to
explain some of these observations. We found that lack of
p14ARF expression in tumours with wild-type p53 disrupts the
p53 signalling pathway leading to high and uncontrolled Mdm2
protein activities and, therefore, facilitates ONYX-015 replication
(Ries et al, 2000). Through deregulation of Mdm2, p53 is inhibited
from exerting its protective effects after adenoviral infection. Re-
introduction of functional p14ARF into such tumour cells led to
induction of p53 activity and prevented replication of ONYX-
015, but not wild-type adenovirus. This protective effect of
p14ARF is p53 dependent. Re-introduction of p14ARF did not
prevent replication of ONYX-015 in an isogenic cell line, in which
the wild-type p53 gene has been deleted by homologous recombi-
nation (Ries et al, 2000). Thus, genetic lesions affecting molecular
factors within the p53 pathway other than mutations of p53 itself
can render cells permissive for ONYX-015. Finally, it should be
noted that E1B55K has functions other than neutralizing p53, such
as promoting the export of late viral mRNAs (Babiss et al, 1985;
Halbert et al, 1985). In some cells types, differences of replication
efﬁcacy between wild-type adenovirus and ONYX-015 might be
explained by these p53-independent functions of E1B55K.
Until recently, the prevailing view was that adenovirus had
developed strategies to negate p53-dependent effects in order
to circumvent cellular mechanisms for inhibition of viral repli-
cation. In recent studies, it was speculated that wild-type p53
might actually be required for efﬁcient adenovirus replication
(Dix et al, 2000) despite the fact that several cell lines with various
mutations in the p53 gene (including homozygous deletions)
supported efﬁcient replication of wild-type adenovirus and
ONYX-015. The study fails to assess the actual production of a
new virus in cell lines with wild-type p53 and did not examine
infected cells for evidence of apoptosis. Therefore, the experiments
did not distinguish between cell death due to viral replication or
apoptosis. The debate on the role of p53 as a regulator of adeno-
virus replication was extended recently by an interesting study in
which researchers used a mutant p53 molecule containing
sequences from the p53 homologue p73 to analyze p53 dependent
effects on virus replication (Koch et al, 2001). According to the
authors, this chimeric molecule cannot be degraded by E1B55K
while the function of p53 as a transcription factor remains fully
preserved. Curiously, this mutant p53 molecule had no inhibitory
effect on replication of wild-type adenovirus or ONYX-015 in
normal or tumour cells (Koch et al, 2001). This study, however,
failed to demonstrate the functionality of the p53/p73 chimera
convincingly, in particular its responsiveness to oncogene or
DNA-damage-induced signals. Their analysis of transcriptional
targets of p53 is restricted to p21WAF1. Of particular importance,
they do not examine expression of the proapoptotic gene Bax.
Experiments in primary cells have shown that the suppression of
ONYX-015 replication by p53 in normal cells is preferentially
mediated through Bax (L Johnson and C O’Shea, personal commu-
nication). The clinical studies also do not support the view that
ONYX-015 replicates in normal cells with functional p53. As
discussed in the following paragraphs, ONYX-015 has no demon-
strable toxicity in animals or humans, and in some clinical
studies can be shown to replicate in tumours lacking functional
p53.
Preclinical animal studies
Subsequent to the initial investigations in cell lines, studies in
tumour bearing mice were performed to evaluate the anti-tumour
efﬁcacy of ONYX-015, dose-limiting toxicities, effects of schedul-
ing, and the possibility of combining this treatment in a
meaningful way with other established therapeutic modalities.
Initial experiments in xenograft models of human tumours
(harbouring wild-type p53 or mutated p53) demonstrated signiﬁ-
cant anti-tumour activity of intratumourally administered ONYX-
015 in tumours with mutated (Heise et al, 1997). In contrast,
ONYX-015 injection into tumours derived from wild-type p53
glioblastoma cells had no inhibitory effect on tumour growth.
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demonstrated by in situ hybridization and immunohistochemistry,
this was not the case in the wild-type p53 cells (Heise et al, 1997).
In addition, mixing experiments were performed in which only a
fraction of subcutaneously injected cells has been pre-incubated
with ONYX-015. As few as 5% of the injected cells needed to be
infected to completely abolish tumour growth of cells with mutant
p53, whereas no effect on tumour formation by cells with wild-type
p53 cells was unchanged (Heise et al, 1999a). These data correlate
well with in vitro studies and demonstrated signiﬁcant therapeutic
efﬁcacy of ONYX-015 in vivo with evidence for p53-dependent
virus replication.
Subsequent studies examined xenograft tumours derived from a
laryngeal cancer cell line, HLaC, that showed an increased survival
without achieving complete remissions following ONYX-015 treat-
ment. Although these cells harbour wild-type p53, the pathway is
partly inactivated because of a mutation of the p14ARF tumour
suppressor gene. Different dosing schedules were tested and
showed that virus application for ﬁve consecutive days was super-
ior to a one-time application of the same total virus dose (Heise et
al, 1999a). Furthermore, of particular importance for the subse-
quent clinical development of ONYX-015, it was noted that
efﬁcacy against this tumour was signiﬁcantly enhanced when the
virus was combined with the chemotherapeutic agents 5-FU or
cisplatin (Heise et al, 1997). Similarly, combining the virus with
radiotherapy resulted in enhanced anti-tumour efﬁcacy (Rogulski
et al, 2000a). It is conceivable that in tumour cells harbouring
wild-type p53 the pro-apoptotic effect of chemotherapy and radio-
therapy, respectively, is mediated through DNA-damage dependent
activation of p53 (a signalling event that occurs independently of
p14ARF). It is well established that the adenovirus E1A protein
enhances this effect. The data support the use of ONYX-015 in
tumours independently of their p53 status if the treatment is
combined with chemotherapy.
Experiments in mice bearing bilateral ﬂank xenograft
tumours have addressed the clinically relevant question of
whether there is systemic spread of virus to distant tumour
sites. While intratumoural injection of ONYX-015 resulted in
immunohistochemical detection of virus replication in contral-
ateral, non-injected, tumours, growth of these contralateral
tumours was not inhibited (Heise et al, 1999b). Nevertheless,
growth of contralateral new tumours was reduced following virus
injection into established tumours. These results implied that
systemic virus spread to distant tumours occurs with suppression
of microscopic tumours. The number of infected cells at estab-
lished distant tumours, however, was apparently too low to
initiate progressive, tumour-ablative virus replication. As a possible
solution to this limitation, intravenous (iv) application of the virus
was investigated in subsequent studies in mice with established
subcutaneous xenograft tumours derived from a series of human
tumour cell lines, i.v. injection of ONYX-015 caused signiﬁcant
growth inhibition and increased survival in all cases (Heise et al,
1999b). In situ hybridization experiments demonstrated spread of
virus replication throughout the tumour, beginning in focal areas
near blood vessels (Heise et al, 1999b). However, complete remis-
sions occurred in only a small number of tumours. The reduced
efﬁcacy of ONYX-015 given systemically could be the result of a
number factors including deﬁcient adenovirus receptor expression,
extensive removal of virus by hepatic up-take, and effects of the
immune system despite the impaired immunity. These issues will
be discussed in the context of clinical studies (below). Nevertheless,
the anti-tumour efﬁcacy of systemically administered ONYX-015
was dramatically improved when the virus was combined with
the chemotherapeutic agent 5-FU. While treatment with ONYX-
015 alone induced only one complete remission (CR) and with
5-FU two CR (seven animals per group), six CRs were observed
in animals that received the combined treatment (Heise et al,
1997).
CLINICAL EXPERIENCE
Intratumoural application of ONYX-015
Based on the encouraging preclinical experience with ONYX-015,
clinical trials have been initiated in patients with squamous
carcinomas of the head and neck (HNSCC), and pancreatic
cancer. Additional studies were performed in patients with
premalignant oral dysplasia, ovarian cancer, and liver metastases
from colorectal cancer (Figure 2). As these studies have not been
published in peer-reviewed journals yet, they will not be
discussed in this review.
Phase-I studies involved single intratumoural injections of
ONYX-015. In all cases, escalation of the virus dose was possible
without that a dose-limiting toxicity was observed and the maxi-
mum virus dose that could be administered was based on
manufacturing capabilities (Ganly et al, 2000; Mulvihill et al,
2001). The spectrum of side effects was similar: Most frequently
observed were fever, nausea, chills, and a ﬂu-like syndrome (Table
1). In addition, patients with HNSCC experienced pain at the
injection site. No signiﬁcant liver toxicity occurred and there were
no signs of disseminated intravascular coagulation. Based on these
results, intratumoural injection of ONYX-015 appears to be safe.
With regard to the efﬁcacy of ONYX-015 for human tumours,
the largest experience to date is in HNSCC. Evaluation of tumour
response at the injected tumour sites showed that three of the 22
patients (14%) experienced objective, partial, tumour responses
and an additional ten patients (45%, including two minor
responses) showed stabilization of their disease. While detection
of viral DNA using in situ hybridization technology revealed
evidence of intratumoural virus replication in four tumour biopsies
that all harboured mutant p53, no statistically signiﬁcant correla-
tion between p53-status and tumour response could be
established. It should be noted, however, that these biopsies were
obtained on day eight following injection of the virus, demonstrat-
ing prolonged intratumoural replication of ONYX-015. In the same
study, the humoural immune response to virus injection was
assessed. While 59% of the patients had pre-existing neutralizing
antibodies to adenovirus, all but one patient developed increased
antibody levels after treatment (Ganly et al, 2000). However, the
presence of pre-existing antibodies did not correlate with tumour
response. This ﬁnding agrees with the experience using non-repli-
cating adenoviruses for the delivery of p53 into tumour cells, where
a correlation between neutralizing antibodies and transgene deliv-
ery could not be established (Clayman et al, 1998).
A subsequent phase-II study was conducted in patients with
recurrent HNSCC. As a consequence of the animal studies
described above, which had shown that sequential doses of virus
are superior to single applications, two dosing regimens were
examined. The therapy consisted either of intratumoural injection
for ﬁve days (standard regimen) or twice daily for two consecu-
tive weeks (hyperfractionated regimen). Main side effects were
mild to moderate fever and pain at the site of injection; the
latter was particularly frequent in patients receiving hyper-
fractionated therapy.
In patients receiving standard therapy, objective responses were
observed in 14% (including three out of 40 patients that achieved
complete responses), which were signiﬁcantly correlated with the
presence of p53 gene mutations. In an additional 12 patients (41%)
the disease was stabilized. There were no signiﬁcant differences in
therapeutic activity between the treatment schedules. Interestingly,
in the ﬁrst cycle of treatment viral genomes were detected in the
peripheral blood of about half the patients 24 h after the last virus
administration, a ﬁnding that was interpreted as a sign of intratu-
moural virus replication. The number of patients with detectable
virus declined signiﬁcantly in subsequent cycles. In parallel, serum
levels of neutralizing antibodies increased dramatically (mean titer
at baseline, 1:51; titer after cycle 1, 1:11869). It is most likely that
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clearance of virus particles shed from the tumours into the peripheral
blood. To what extent antibodies interfere with intratumoural virus
spread is unclear at this time. Nevertheless, this study demonstrated
again the favourable toxicity proﬁle of ONYX-015 and showed
unambiguously the anti-tumour activity of the virus in a subset of
patients, in particular those with a mutated p53 gene.
As discussed above, preclinical studies suggested a potential
synergistic effect of chemotherapy and ONYX-015. Based on these
results, a phase-II study was initiated, aimed to evaluate the combi-
nation of ONYX-015 and standard, cisplatin-based chemotherapy
in patients with recurrent HNSCC. The results mirrored the precli-
nical data, including the frequent occurrence of complete
remissions. Of 30 evaluable patients, 19 (63%) experienced an
objective tumour response, including eight (27%) complete
responses. Most interestingly, none of the 19 tumours that had
shown objective responses progressed during the observation time
of this study. In patients with multiple lesions, only the largest
and clinically most relevant tumour had been injected, so that
the other tumours served as intra-patient controls. Despite the fact
that the injected tumours were generally larger, nine of 11
responded, in contrast to three of 11 non-injected tumours. This
statistically signiﬁcant difference represents one of most convincing
pieces of evidence for a speciﬁc anti-tumour effect of ONYX-015.
Encouraged by these results, a clinical phase-III study has been
initiated and is ongoing; patients with ﬁrst relapse of HNSCC
are receiving either combined cisplatin-based chemotherapy and
intratumourally injected ONYX-015 or standard chemotherapy.
Systemic application of ONYX-015
Intravenous administration of ONYX-015 has been explored in a
pilot study of advanced lung tumours (Nemunaitis et al, 2001).
In this study, patients received intravenous injections of up to
2610
13 viral particles. The main side effects included, again, fever
and rigours. In contrast to the previous study, however, a transient,
dose-dependent increase of serum aminotransferase was also
observed. In the context of recent concerns regarding the safety
of adenovirus vectors, it is important to note that these changes
were mild (maximal four-fold increase of serum ALT) In one
patient, intratumoural virus replication was documented although
no objective tumour responses were observed. The reasons for a
potential lower efﬁcacy of systemic administration of ONYX-015,
relative to tumour injection, will be discussed below.
Problematic bio-distribution and mechanisms of virus
resistance
It is well documented in animal models that hepatic uptake of
systemically injected adenovirus is efﬁcient, reducing the number
of infectious virus particles signiﬁcantly that may reach the target
tumour (Fechner et al, 1999). Another factor is the frequent
Table 1b Clinical studies with ONYX-015 published as abstracts
Indication/ No. of Viral Route of Treatment Chemo- Main adverse Best
Author study type patients dose administration schedule therapy events response (%)
Rudin (Rudin et al, 1999) Oral dysplasia 10 10
10 pfu Oral mouthwash Daily 65, – – CR 3 (67)
phase II q 28 days PR
a 2 (20)
Reid (Reid et al, 2001) Colorectal cancer 25 2610
8 Infusion into Day 1, 8, 5-FU/ Fever, ﬂu-like CR 0 (0)
liver metastases –2610
12 hepatic artery q 28 days Leucovorin symptoms PR 2 (8)
particles
Hecht (Hecht et al, 2000) Pancreatic carcinoma 18 10
9–10
10 Intratumoural Weekly 68 Gemcitabine Fever, PR 2 (11)
phase I/II pfu injection
b sepsis MR 1 (6)
Bergsland (Bergsland et al, 1998) Liver metastases 16 10
8–10
11 Intratumoural Day 1, – Flu-like symptoms MR 2 (13)
phase I pfu injection q 28 days SD 9 (60)
Vasey (Vasey et al, 2000) Ovarian cancer 16 10
9–10
11 Intraperitoneal Daily 65, – Abdom. Pain, ﬂu-like N/A
phase I pfu infusion q 21 days symptoms
aReduction of grade of dysplasia;
bEndoscopic ultrasound guided.
Table 1a Peer reviewed publications on clinical studies with ONYX-015
Indication/ No. of Viral Route of Treatment Chemo- Main adverse Best
Author study type patients dose administration schedule therapy events response (%)
Ganly (Ganly et al, 2000) Recurrent head 22 10
7–10
11 Intratumoural Single – Fever, nausea PR
c, 3 (14)
and neck cancer pfu
a injection injection chills
Phase I
Mulvihill (Mulvihill et al, 2001) Pancreatic 23 10
8–10
11 Intratumoural Single – Flu-like symptoms, MR
d, 6 (26)
carcinoma pfu injection injection fever SD
e, 10 (43)
Phase I
Nemunaitis (Nemunaitis et al, 2001) Metastatic 10 2610
10 Intravenous Day 1, 8, 15, Carboplatin, Fever, rigor, MR, 1 (10)
solid tumours 72610
13 injection q 21 days taxol LFT
g: SD, 8 (80)
Phase I particles
b
Nemunaitis (Nemunaitis et al, 2000) Recurrent head 40 10
10 pfu Intratumoural Day 1–5, – Pain at injection CR
f, 3 (8)
and neck cancer injection q 21 days
h site, fever, ﬂu- PR, 2 (5)
Phase II like symptoms
Khuri (Khuri et al, 2000) Recurrent head 37 10
10 pfu Intratumoural Day 1–5, 5-FU Pain at injection CR, 8 (27)
and neck cancer injection q 21 days cisplatin site, fever, ﬂu- PR, 11 (36)
Phase II like symptoms
aPlaque forming units;
bViral particles;
cPartial response;
dMinor response;
eStable disease;
fComplete response;
gLiver function tests;
hAdditional 10 patients received ‘hyperfrac-
tionated’ treatment, see text.
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In the clinical studies with ONYX-015, the majority of patients
presented with neutralizing antibodies and almost all showed a
dramatic increase in antibody following the ﬁrst virus injection.
It has been demonstrated that anti-adenovirus antibodies are
important inhibitors of antitumour activity of systemically admi-
nistered adenoviruses and it has been proposed to use methods
such as immunoapheresis to remove these antibodies from the
circulation before initiation of treatment (Chen et al, 2000). Our
knowledge about possible mechanisms that are contributing to
resistance of target cells against virus infection is still limited.
Nevertheless, it is evident that adenovirus-based therapies depend
critically on the ability of the virus to enter target cells, a process
for which the recently identiﬁed Coxsackie- and Adenovirus Recep-
tor (CAR) is most important as it mediates the attachment of the
adenovirus ﬁber protein to the cell surface (Bergelson et al, 1997).
Recent reports as well as our own experience indicate that CAR
expression is frequently lost or reduced in highly malignant
tumours (Li et al, 1999). Taken together, these mechanisms poten-
tially diminish the amount of virus available to target cells, notably
in the context of systemically administered virus. In addition, inter-
cellular barriers, including tissue stroma (containing collagen ﬁbers
and CAR-negative ﬁbroblasts) and necrotic areas within the
tumour, could limit the spread of ONYX-015 within a tumour.
At this point it is unclear, whether pro-inﬂammatory cytokines,
including IL-2 and TNF are inhibiting or promoting viral spread.
Equally uncertain is the contribution of T cells. In addition to
the deletion of the E1B55k gene ONYX-015 harbours a deletion
of the E3B region, which contains the gp19k gene that is able to
inhibit MHC class-I antigen presentation at the cell surface. It is
therefore conceivable that the recognition of adenovirus antigens
leads to elimination of infected cells before production of
ONYX-015 is sufﬁcient for successfully infecting neighboring cells.
However, it is also possible that the co-presentation of tumour-
and viral antigens triggers an immune response against tumour
cells, in which case ONYX-015 would promote vaccination against
tumour antigens. These questions are a subject of current studies.
Nevertheless, mathematical models of virus replication in an
immune-competent host suggest that the immune-response to
ONYX-015 could play a decisive role for the success of this treat-
ment (Wodarz, 2001). This is supported by recent studies
illustrating a balance between growth of xenograft tumours in mice
and replication of wild-type adenovirus, resulting in detection of
replicating virus 100 days following infection without reduction
of the tumour mass (Harrison et al, 2001).
Future perspectives
The results from the clinical phase-III study in HNSCC will be
available in the ﬁrst half of the year 2002 and will have a crucial
impact on the further development of this therapeutic approach.
In addition, future studies of ONYX-015 might include new strate-
gies to overcome the limitations described above. These include the
design of replication-restricted viruses with altered receptor speci-
ﬁcity, capable of circumventing the problem of loss of expression
of adenovirus receptors on target cells, in particular CAR, by utiliz-
ing other, cancer speciﬁc proteins as alternate receptors. We are
currently investigating the possibility of pharmacological restora-
tion of CAR expression at the surface of cancer cells (Anders et
al, manuscript in preparation). To overcome the need to infect
all tumour cells to achieve complete remission, new versions of
ONYX-015 have been created that deliver pro-drug converting
enzymes to tumour cells, which create high local concentrations
of cytotoxic compounds following systemic administration of
non-toxic substrates. For example, an E1B55K-deleted adenovirus
has been devised, expressing herpes simplex virus-thymidine kinase
(HCV-TK), which catalyzes phosphorylation of gancyclovir result-
ing in highly cytotoxic metabolites (Wildner and Morris, 2000).
ONYX-015 is an interesting new agent for the treatment of
solid tumours that shows unambiguous evidence of antitumour
activity in a broader range of tumours than initially anticipated.
However, the biological mechanisms deﬁning the interaction of
this virus with its human host need further exploration. Based
on this knowledge, strategies can be developed to overcome
problems of bio-distribution and resistance, and, ultimately, to
increase the efﬁcacy of systemically administered ONYX-015.
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